论文部分内容阅读
免疫检查点在肿瘤免疫逃逸中起着至关重要的作用。细胞毒T淋巴细胞相关抗原4(CTLA-4)、程序性死亡受体-1(PD-1)及其配体PD-L1是近年研究比较透彻的免疫检查点分子。多项临床试验证实,CTLA-4和PD-1/PD-L1这些免疫检查点的抑制剂在控制恶性肿瘤生长、维持疾病稳定及延长患者生存时间上取得了令人瞩目的效果。卵巢癌是免疫原性肿瘤,将标准治疗与免疫治疗联合有望进一步改善患者预后。本文对免疫检查点分子在卵巢癌的表达、免疫检查点抑制剂在卵巢癌治疗中的进展及临床试验结果进行综述。
Immune checkpoints play a crucial role in tumor immune escape. Cytotoxic T lymphocyte associated antigen 4 (CTLA-4), PD-1 (PD-1) and its ligand, PD-L1, are relatively well studied immune checkpoint molecules in recent years. Several clinical trials have confirmed that inhibitors of CTLA-4 and PD-1 / PD-L1 at these immune checkpoints have achieved remarkable results in controlling the growth of malignant tumors, maintaining disease stability and prolonging the survival of patients. Ovarian cancer is an immunogenic tumor, the standard treatment and immunotherapy combined is expected to further improve the prognosis of patients. In this paper, the immune checkpoint molecular expression in ovarian cancer, immune checkpoint inhibitor in the treatment of ovarian cancer progress and clinical trial results are reviewed.